Immix Biopharma, Inc. (IMMX)
Immix Biopharma develops CAR T cell therapies, led by NXC-201, for AL amyloidosis and other serious diseases. It last closed at $7.20 on Nov 17, down 3.74% on the day. The average 12-month price target from 3 analysts is $27.67 (+284.3% from the last close), with a high of $30.00 and a low of $26.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From IMMX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on IMMX in the past 90 days. The average target is $27.67, with a high of $30.00 and a low of $26.00, compared with the last close of $7.20.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | HC Wainwright & Co. | Target raised | Buy | $25 → $27 |
| Sep 29 | Needham | Target raised | Buy | $21 → $30 |
| Sep 15 | Mizuho | Maintained | Buy | $26 |
| Aug 11 | Morgan Stanley | Maintained | Buy | $19 |
| Aug 10 | HC Wainwright & Co. | Target raised | Buy | $20 → $25 |
Technical Analysis
The stock is 11% below its 20 day and 33% below its 50 day average. It is 34% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 37), near oversold. The nearest support is the swing low (Nov 5) at $7.12, and the nearest resistance the Pivot at $7.29.
| RSI (14) | 37.44 | Weak, oversold below 30 | Neutral |
| MACD | -0.47 | Above its signal line | Bullish |
| Stochastic | 21.9 | Middle of its range | Neutral |
| ADX (14) | 32.7 | Trending down | |
| Williams %R | -95.5 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -146.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −6.6% | Change over 10 sessions | Bearish |
| ATR (14) | $0.63 | Typical daily range, 8.8% of price |
| RSI (14) | 39.35 | Weak, oversold below 30 | Neutral |
| MACD | -0.37 | Below its signal line | Bearish |
| Stochastic | 7.3 | Near the bottom of its range | Oversold |
| ADX (14) | 22.8 | Weak trend | |
| Williams %R | -99.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -105.1 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −40.7% | Change over 10 sessions | Bearish |
| ATR (14) | $1.49 | Typical daily range, 20.7% of price |
What happened before
See how IMMX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IMMX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in IMMX in the last 90 days.
IMMX Institutional Ownership
Full report →- ▲103 buying vs 32 selling
- ▲Held by funds +11.5 pts
- ▲Funds holding +28
- ●Superinvestors: 1 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 137 | 109 | +25.7% |
| In funds' top 10 | 4 | 3 | +33.3% |
| Held by funds | 78.6% | 67.1% | +11.5 pts |
| New / increased | 41 / 62 | 43 / 34 | +33.8% |
| Reduced / sold out | 19 / 13 | 13 / 11 | +33.3% |
| Put/call ratio | 0.00 | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMMX is in one of them and how their past IMMX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IMMX in an article yet. Here's the latest on the wider market.
About Immix Biopharma
Immix Biopharma is a biopharmaceutical company based in Los Angeles, California. It develops chimeric antigen receptor (CAR) T cell therapies, led by its candidate NXC-201, for AL amyloidosis, a serious disease in which an abnormal protein builds up in organs such as the heart and kidneys. The lead candidate is in clinical trials and is not yet approved for sale. The company's target patients have this disease or other serious conditions where CAR T therapy is not yet an approved treatment.
- Headquarters
- Los Angeles, CA

